PFIZER INC (PFE)

US7170811035 - Common Stock

31.94  -0.16 (-0.5%)

PFIZER INC

NYSE:PFE (9/28/2023, 8:43:10 AM)

31.94

-0.16 (-0.5%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-01 2023-08-01/bmo
Earnings (Next)10-30 2023-10-30/bmo
Ins Owners0.03%
Inst Owners103.92%
Market Cap180.33B
Shares5.65B
PE6.63
Fwd PE9.59
Dividend Yield4.99%
Analysts70.97
IPO01-17 1944-01-17
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PFE Daily chart

Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 83,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The firm operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK 10017

P: 12127332323.0

CEO: Albert Bourla

Employees: 83000

Website: https://www.pfizer.com/

PFE News

News Imagean hour ago - Yahoo FinanceGSK lifts growth ambitions for HIV business on long-acting drug

GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection. The ViiV business, in which Pfizer and Shionogi hold small stakes, is a key element of a push by group CEO Emma Walmsley to improve investor confidence in the strength of GSK's drug development pipeline, which has lagged rivals. Strong sales of medicines for HIV, the virus that causes AIDS, were one of the drivers behind the company's improved guidance for 2023 earnings, issued in July, alongside continued growth in demand for GSK's shingles vaccine.

News Image3 hours ago - InvestorPlaceSmart Picks: 7 Blue-Chips Trading Below True Value

Undervalued blue-chip stocks make more sense than ever as the tech sell off causes a pivot into more conservative shares.

News Image4 hours ago - The Business JournalsThe Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan
News Image8 hours ago - IssueWireKevin Dodelande's iMi launches into early cancer detection

In this age of technological advances, the power of Big Data combined with Artificial Intelligence (AI) is opening up new possibilities through early diagnosis to increase patient life expectancy.

News Image18 hours ago - Market News VideoNotable Wednesday Option Activity: LITE, BXP, PFE
News Image19 hours ago - InvestorPlaceDon’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher

These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.

PFE Twits

Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example